New meta-analysis show patient demographics—as well as their pre-existing comorbidities and COVID-19 vaccination status—may significantly define their risk of long-term conditions.
Kevin Kunzmann
Advertisement
Kevin Kunzmann is the associate editorial director for HCPLive. Prior to joining parent company MJH Life Sciences in 2017, he worked as a health care and government reporter for The Pocono Record, and as a freelance writer for NJ Advance Media, The Express-Times, The Daily Journal, and more. He graduated from Rowan University with a degree in journalism in 2015. In his spare time, he enjoys reading, cooking, running his dog, and complaining about the Mets. Follow him on Twitter @NotADoctorKevin or email him at kkunzmann@mjhlifesciences.com.
Articles by Kevin Kunzmann
New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.
A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.
An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.
New cohort analysis data show women with fibromyalgia are at an increased risk of depression—which is also correlated with a worse life expectancy over 8 years.
An international review of data show certain antidepressants may benefit conditions like fibromyalgia, but many trials are actually inconclusive.
New survey data from Europe show how factors of the pandemics impacted long-term rheumatoid arthritis management.
A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.
A comparative trial of biologic agents suggest IL-17A inhibitors may more significantly improve skin clearance in comorbid patients.
The sixth indication for the JAK inhbitior from AbbVie makes it the first in class approved for both nr-axSpA and ankylosing spondylitis.
Developing research into the specific alterations of dysbiosis and diseases like arthritis suggest possibly novel pathways to therapy development.
New data support the continued assessment of the investigative drug for adults with SLE.
Seoyoung C. Kim, MD, ScD, MSCE: Cardiovascular Risks with Hydroxychloroquine in Rheumatoid Arthritis
An interview on new findings suggesting baseline heart failure may be an indicator of increased mortality risk in patients treating arthritis with the DMARD.
A team from Vanderbilt identified 4 key predictors from a retrospective analysis of cases since 2020.
New ACR findings supporting rheumatology societies' advocacy for more intensive therapy strategies, with proof of safety.
New late-breaking data from ACR 2021 show the mRNA vaccine may differ in patients dependent on their disease.
Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.
An assessment of a rheumatic disease cohort shows Spike protein antibody response is significantly decreased in vaccinated patients, and may vary by treatment.
Fetal deaths associated with the rheumatic disease have been on the decline, but increased risks persist nonetheless.
Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.
An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.
Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.
A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.
More data from ACR 2021 evidences the risk of minimal response to mRNA vaccines in autoimmune disorder patients on rituximab.
The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.
A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.
New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.
A pandemic-era study suggests rheumatology care teams can capably provide beneficial care via telemedicine to treatment-stable patients.
New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.
The indication granted Monday makes the 2-dose vaccine the very first approved by the FDA for the prescribed prevention of COVID-19.
Advertisement
Advertisement
Advertisement